Cellenkos is developing allogeneic, tissue-targeted regulatory T cell therapies, specifically CK0801, derived from cord blood to replace defective T-REGs that fail to suppress harmful T cell activity. This approach aims to restore immune homeostasis and control autoimmune diseases such as lupus, multiple sclerosis, and rheumatoid arthritis.
Funding
$15M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
In autoimmune diseases and inflammatory disorders, defective regulatory T cells (T-REGS) fail to suppress harmful T cell activity, leading to the body's immune system attacking its own tissues. Current treatments often lack specificity and can have broad immunosuppressive effects.
Solution
Cellenkos is developing CK0801, an allogeneic, tissue-targeted regulatory T cell therapy derived from cord blood, designed to replace defective T-REGS and restore immune homeostasis. CK0801 aims to prevent T cell attacks against the body, thereby controlling autoimmune diseases and inflammatory disorders. The therapy is clinically manufactured using Cellenkos’ proprietary platform, resulting in a product with superior T cell suppression and anti-inflammatory properties. By infusing CK0801, the defective T-REGS are replaced, protecting the body from T cell-mediated damage and leading to disease control.
Target Audience
The primary target audience includes patients suffering from autoimmune diseases and inflammatory disorders such as lupus, multiple sclerosis, rheumatoid arthritis, Crohn’s disease, and bone marrow failure syndromes like aplastic anemia.
Features
- Allogeneic regulatory T cell therapy derived from cord blood.
- Tissue-targeted approach for precise immune modulation.
- Proprietary manufacturing platform for enhanced T cell suppression.
- Designed to replace defective T-REGS and restore immune homeostasis.
- Aims to control autoimmune diseases and inflammatory disorders by preventing T cell attacks.